Skip to main content

Table 2 Baseline antiretroviral resistance

From: Delayed linkage to HIV care among asylum seekers in Quebec, Canada

 Overall (n = 139)First diagnosed in Canada (n = 60)First diagnosed before arrival to Canada (n = 79)
HIV Genotype available80 (58%)57 (95%)23 (29%)
Baseline antiretroviral resistancea
 No60 (75%)45 (79%)15 (65%)
 Yes20 (25%)12 (21%)8 (35%)
  NRTI resistance6 (8%)2 (4%)4 (17%)
  NNRTI resistance17 (21%)12 (21%)5 (22%)
  PI resistance0 (0%)0 (0%)0 (0%)
  II resistance1 (1%)1 (2%)0 (0%)
  Multidrug resistance3 (4%)2 (4%)1 (4%)
  M184 V/I mutation3 (4%)2 (4%)1 (4%)
  K103 N/S mutation11 (14%)7 (12%)4 (17%)
  K65R mutation0 (0%)0 (0%)0 (0%)
  TAMs1 (1%)1 (2%)0 (0%)
  1. aThe denominator for these proportions is the number of patients with available genotypic data (i.e. 80 for overall, 57 for first diagnosed in Canada, and 23 for first diagnosed before arrival to Canada)
  2. II integrase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, TAMs Thymidine analogue mutations